四環醫藥 (00460.HK)：旗下軒竹生物自主研發1類創新藥獲批開展II期臨床試驗

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

四環醫藥 (00460.HK)：旗下軒竹生物自主研發1類創新藥獲批開展II期臨床試驗

阿思達克 07-03 12:03

四環醫藥 (00460.HK)公布，旗下非全資附屬軒竹生物自主研發的1類新藥(口比)羅西尼單藥或聯合醋酸阿比特龍和潑尼松治療轉移性前列腺癌的II期臨床試驗申請已獲國家藥監局批准。公司指，臨床前研究結果表明，針對前列腺癌模型，(口比)羅西尼和醋酸阿比特龍聯用具有顯著的抗腫瘤協同作用。

四環醫藥(00460.HK)

Relevant Stocks

四環醫藥(00460.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

四環醫藥 (00460.HK)：旗下軒竹生物自主研發1類創新藥獲批開展II期臨床試驗

Services

About Us

Agreement Statement